EF Hutton analyst Elemer Piros initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Buy rating and announces Price Target of $38.
JP Morgan Downgrades Vir Biotechnology: Here’s What You Need To Know
JP Morgan downgraded its rating of Vir Biotechnology (NASDAQ:VIR) to Neutral with a price target of $9.00, changing…